In a report released today, Juan C. Sanabria from BMO Capital maintained a Buy rating on National Health Investors, with a price target of $90.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Juan C. Sanabria has given his Buy rating due to a combination of factors, including the positive financial performance of National Health Investors (NHI) in the third quarter of 2025. The company reported a significant beat in Funds Available for Distribution per share (FAD/sh), which exceeded expectations by 8 cents, despite some weaknesses in the Senior Housing Operating Portfolio (SHOP). This strong performance was primarily driven by deferrals, and as a result, the guidance for FAD/sh has been raised to reflect these results.
Furthermore, NHI’s normalized Funds from Operations per share (FFO/sh) also surpassed consensus estimates, showcasing a robust year-over-year growth. The company has made strategic acquisitions, amounting to $75 million at an 8% yield, which further supports its growth outlook. Despite some challenges in the SHOP segment, the overall financial health and strategic initiatives of NHI have led Juan C. Sanabria to maintain a positive outlook on the stock, justifying the Buy rating.
C. Sanabria covers the Real Estate sector, focusing on stocks such as Brixmor Property, National Health Investors, and Ventas. According to TipRanks, C. Sanabria has an average return of 0.5% and a 45.73% success rate on recommended stocks.
In another report released on October 31, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $85.00 price target.